Safety and Efficacy Study of Tendril MRI™ Leads in Standard Bradycardia Pacing Indication (TendrilMRI™)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01528150|
Recruitment Status : Completed
First Posted : February 7, 2012
Results First Posted : August 31, 2016
Last Update Posted : February 4, 2019
|Condition or disease|
Magnetic resonance imaging (MRI) is a diagnostic method to view high quality two and three dimensional images of the body. However, magnetic resonance imaging systems generate three electromagnetic fields that are used to produce an image. These include a static magnetic field, a time varying gradient magnetic field, and a radiofrequency field. All three of these fields interact with implanted devices and could create hazards for the device, the patient, or both. Due to these issues, currently marketed pacemaker systems may be contraindicated for use in an MRI environment.
St. Jude Medical has developed a system, the Accent MRI™ system, comprised of the Accent MRI™ device and the Tendril MRI™ lead, and an investigational MRI Activator™, designed to mitigate such interactions.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||466 participants|
|Target Follow-Up Duration:||12 Months|
|Official Title:||Clinical Investigation to Assess the Safety and Efficacy of the Tendril MRI™ Leads, as a Part of the Accent MRI™ System, in Patients With Standard Bradycardia Pacing Indication.|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||March 2015|
Accent MRI System
Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
- Freedom From RA and RV Lead-related Complications [ Time Frame: up to 12 months post-implant ]Safety of the Accent MRI™ system with the Tendril MRI™ lead will be evaluated in terms of freedom from Right Atrial (RA) and Right Ventricular (RV) lead-related complications for the acute (implant to 2 month visit) and chronic (2 month visit through the 12 month visit) timeframes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01528150
|Principal Investigator:||Rob RW Breedveld, MD||Medical Center Leeuwarden, the Netherlands|